SILONasdaqPharmaceutical PreparationsFiscal year ends December 31

Silo Pharma, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.13−0.05 (-4.24%)

Close on Oct 19, 2026

Market cap: $1.24M
P/E (TTM): –
Dividend yield: –

Silo Pharma, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31
Revenue	0.07	0.07	0.07	0.07	–	0.04	0.04	–	–	–	–	–
Cost of Revenue	0.04	0.01	0.01	0.01	0.01	0.18	0.03	–	–	–	–	–
Gross Profit	0.03	0.07	0.07	0.07	0.07	-0.14	0.01	–	–	–	–	–
Research & Development	2.16	2.37	0.85	1.29	0.69	0.03	–	–	–	–	–	–
Selling, General & Admin	–	–	0.39	0.23	0.16	0.05	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	0.12	0.09	0.08	0.03	0.01	0.04	0.05
Operating Expenses	4.31	4.77	3.92	3.69	2.81	2.20	0.94	0.59	0.49	–	–	–
Total Costs & Expenses	–	–	–	–	–	–	–	–	–	0.07	0.04	0.05
Operating Income	-4.28	-4.71	-3.86	-3.63	-2.74	-2.20	-0.93	-0.59	-0.49	–	–	–
Interest Expense	0.04	0.01	0.00	0.00	0.00	0.00	0	–	–	–	–	–
Interest & Investment Income	0.00	0.33	0.40	0.07	0.00	0.01	–	–	–	0.00	–	–
Income from Equity Investments	–	–	0.00	-0.33	6.66	–	–	–	–	–	–	–
Other Non-Operating Income	0.05	0.31	0.22	-0.28	6.93	-0.46	-0.08	-0.38	0.85	–	–	–
Asset Impairment Charges	0.04	–	–	–	–	0	0.03	0.10	–	–	–	–
Gain (Loss) on Investments	–	–	–	-0.10	6.66	–	–	-0.73	-0.16	0.10	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	0.00	–	–	–	–	–	–	–
Pretax Income	-4.23	-4.39	-3.63	-3.91	4.18	-2.67	–	–	–	–	–	–
Income Tax Expense	–	–	–	–	0.02	–	–	–	–	–	–	–
Income from Continuing Operations	–	-4.39	-3.63	-3.91	4.16	-2.67	–	–	–	–	–	–
Income from Discontinued Operations	–	–	-0.07	0.00	-0.25	-0.37	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	3.90	-3.04	-1.01	-0.97	–	–	–	-0.05
Minority Interest in Earnings	–	–	–	3.91	3.90	–	–	–	–	–	–	–
Net Income	-4.23	-4.39	-3.70	-3.91	3.90	-3.04	-1.01	-0.97	0.36	–	-0.04	-0.05
Preferred Dividends	–	–	–	–	1.40	0.07	–	–	–	–	–	–
Net Income to Common	–	–	–	-3.91	2.50	-3.04	-1.01	–	–	–	–	–
EPS (Basic)(per share)	-7.50	-17.85	-18.00	–	30.00	-37.50	-30.00	-15.00	7.50	–	0.00	0.00
EPS (Diluted)(per share)	-7.50	-17.85	-18.00	–	30.00	-37.50	-30.00	-15.00	7.50	–	0.00	0.00
Shares Outstanding (Basic, Weighted)(shares)	0.56	0.25	0.21	0.15	0.13	0.09	0.03	0.07	–	0.04	0.04	0.04
Shares Outstanding (Diluted, Weighted)(shares)	0.56	0.25	0.21	0.15	0.13	0.09	0.03	0.07	0.07	0.04	0.04	0.04
Total Interest Income	–	–	–	0.07	0.00	–	–	–	–	–	–	–
Net Interest Income	–	–	–	–	0.00	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: -14.8%
Operating margin: -8250.5%
Net margin: -8269.5%
Return on equity, FY2025: -74.6%

Financial strength

Current ratio: 5.36
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 307.5%

Valuation

P/E ratio: –
Price to sales: 22.95
Price to book: 0.25
Dividend yield: –